Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Cantor Fitzgerald
Daiichi Sankyo
US Army

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,033,645

« Back to Dashboard

Summary for Patent: 6,033,645

Title: Methods for diagnostic imaging by regulating the administration rate of a contrast agent
Abstract:Methods for providing an image of an internal region of a patient. Embodiments of the methods involve administering to the patient a contrast agent which comprises a vesicle composition comprising, in an aqueous carrier, a gas or gaseous precursor and vesicles comprising lipids, proteins or polymers. The patient is scanned using diagnostic imaging, such as ultrasound, to obtain a visible image of the region. The contrast agent is administered to the patient at a rate to substantially eliminate diagnostic artifacts in the image. The methods are particularly useful for diagnosing the presence of any diseased tissue in the patient.
Inventor(s): Unger; Evan C. (Tucson, AZ), Matsunaga; Terry (Tucson, AZ), Fritz; Thomas A. (Tucson, AZ), Ramaswami; Varadarajan (Tucson, AZ)
Application Number:08/666,129
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Formulation;

No matches for this query

International Patent Family for Patent: 6,033,645

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office0930844► Subscribe
European Patent Office0831932► Subscribe
European Patent Office0959908► Subscribe
European Patent Office1146911► Subscribe
European Patent Office1444991► Subscribe
Hong Kong1019699► Subscribe
JapanH11507638► Subscribe
Japan4215820► Subscribe
Japan2000513357► Subscribe
Russian Federation2199348► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus